GSK's Belantamab Among Drugs Seeking EU Approval Nod
Second Time Around For GSK's BCMA-Targeting Therapy
Executive Summary
GlaxoSmithKline's potential multiple myeloma treatment is one of several new products that could get an EU marketing thumbs up from the European Medicines Agency this week.
You may also be interested in...
EMA Says Yes To GSK’s Belantamab But Rejects Tagraxofusp & Emapalumab
GlaxoSmithKline's first-of-its kind treatment for multiple myeloma is among 11 new medicines that have won an EU approval nod from the European Medicines Agency this week.
GW Pharma Among Myriad Hopefuls Seeking Extended Indications In EU
Applications to widen the therapeutic indications of up to 20 approved drugs will be decided on this week at the European Medicines Agency.
EMA’s CHMP Is Set To Adopt Position On Another Avastin Biosimilar
The market for biosimilar Avastin is set to form imminently, with two players holding final approvals from the European Commission waiting in the wings. In the coming days, the EMA’s Committee for Medicinal Products for Human Use is likely to issue an opinion on a further application.